Corteva (CTVA) Q3 2025 Earnings Transcript

Corteva raised 2025 operating EBITDA guidance to $3.8 billion-$3.9 billion, up 14% at the midpoint, and lifted operating EPS guidance to $3.25-$3.35, or 28% growth at the midpoint. The company also reaffirmed $1.9 billion in free cash flow, expects $1 billion of share repurchases, and said the planned Seed/Crop Protection separation remains on track for 2H 2026. Year-to-date organic sales rose 6%, operating EBITDA margin expanded about 320 bps over nine months, and management gave a first look at 2026 EBITDA of roughly $4.1 billion.

Analysis

CTVA is turning into a cleaner story than the headline valuation implies: the split is not a defensive breakup, it is an optionality unlock. The market is still valuing this like a slow-moving ag input conglomerate, but the real second-order effect is that the Crop Protection asset should re-rate closer to a specialty chemicals platform while Seed becomes a high-moat genetics/IP compounder with a different capital intensity profile. That dispersion usually matters more than the aggregate EBITDA delta, because it opens the door to multiple expansion on both sides once standalone financials expose the margin and cash conversion profiles more transparently.

The more interesting near-term setup is that the company is likely under-earning the separation narrative into 2026. The business is already generating enough controllable savings and mix improvement that even moderate top-line normalization can keep EBITDA growing in the mid-single digits, while buybacks continue to shrink the equity base. That combination creates a path where EPS can compound faster than EBITDA for a year or two, which is often the period when investors overpay for quality defensives in cyclically weak end markets.

The main risk is that the market extrapolates the current Brazilian and crop-chem stabilizing environment too far. If LatAm pricing stays weak or receivables deteriorate further, the separation can surface more stranded costs than management is admitting today, and the first-year standalone earnings power could come in below the current implied sum-of-the-parts. The contrarian issue is that consensus may be underestimating how much of the 2026 outlook already depends on volume resilience; if acreage shifts or weather disappoint, the easy margin gains slow and the stock becomes more of a story stock than a fundamentals compounding story.

Key Decisions for Investors

• Go long CTVA on pullbacks over the next 1-3 months with a 12-month view; the setup is attractive if the market continues to price it as a single entity. Risk/reward improves into the February guide update if management reiterates the split timeline and 2026 EBITDA framework.
• Pair trade: long CTVA / short an agriculture input laggard with weaker pricing power and less visible margin expansion. The thesis is relative multiple expansion driven by better capital returns, cleaner segment visibility, and stronger standalone ROIC.
• Buy medium-dated CTVA call spreads into any post-earnings consolidation. Best payoff comes if the market starts assigning separation value before detailed pro forma disclosures; downside is limited to premium if Brazil or FX weakens.
• If you own CTVA already, trim only if it approaches a valuation that assumes flawless 2026 execution. The better risk control is to hold through the February catalyst, when separation details should reduce uncertainty and re-rate the name.
• Watch for a short opportunity only if working capital or LatAm credit metrics deteriorate over the next 1-2 quarters; that would be the first signal that the current margin narrative is being flattered by timing and not just structural improvement.